2023
Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma
Chen E, Kardosh A, Nabavizadeh N, Foster B, Mayo S, Billingsley K, Gilbert E, Lanciault C, Grossberg A, Bensch K, Maynard E, Anderson E, Sheppard B, Thomas C, Lopez C, Vaccaro G, Group O. Phase 2 study of preoperative chemotherapy with nab‐paclitaxel and gemcitabine followed by chemoradiation for borderline resectable or node‐positive pancreatic ductal adenocarcinoma. Cancer Medicine 2023, 12: 12986-12995. PMID: 37132281, PMCID: PMC10315770, DOI: 10.1002/cam4.5971.Peer-Reviewed Original ResearchConceptsNab-paclitaxelNeoadjuvant treatmentDefinitive resectionResection rateAdverse eventsPancreatic adenocarcinomaOpen-label phase 2 trialNode-positive pancreatic cancerLong-course chemoradiationNab-paclitaxel 125Neoadjuvant treatment strategiesOperable pancreatic adenocarcinomaRadiographic response rateCommon adverse eventsR0 resection ratePhase 2 studyPhase 2 trialProgression-free survivalProspective interventional trialNegative surgical marginsTreatment completion ratesPancreatic ductal adenocarcinomaIntensity-modulated radiationGemcitabine 1000Positive nodes
2018
Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival
Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer JM, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, Coussens LM, Sheppard BC, Wong MH. Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Science Advances 2018, 4: eaat7828. PMID: 30214939, PMCID: PMC6135550, DOI: 10.1126/sciadv.aat7828.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkers, TumorCarcinoma, Pancreatic DuctalCell FusionCell Line, TumorCell SurvivalEpithelial CellsFemaleGreen Fluorescent ProteinsHumansHybrid CellsKaryotypingMacrophagesMaleMice, Inbred C57BLMice, TransgenicNeoplastic Cells, CirculatingPancreatic NeoplasmsTumor MicroenvironmentXenograft Model Antitumor AssaysConceptsNeoplastic cellsNumerous neoplastic cellsHuman cancer patientsUrgent medical needPotential therapeutic targetTumor-bearing miceLate-stage progressionHigh lethality rateFuels tumor progressionIdentification of biomarkersOverall survivalDisease stagePeripheral bloodCancer patientsTumor stagingMetastatic spreadNovel biomarkersTherapeutic targetBiologic mechanismsSolid tumorsMedical needMetastatic behaviorTumor progressionCancer highlightLethality rate
2011
Predicting malignant intraductal papillary mucinous neoplasm: a single-center review
Cone M, Rea J, Diggs B, Douthit M, Billingsley K, Sheppard B. Predicting malignant intraductal papillary mucinous neoplasm: a single-center review. The American Journal Of Surgery 2011, 201: 575-579. PMID: 21545902, DOI: 10.1016/j.amjsurg.2011.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryDiagnosis, DifferentialEndosonographyFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedPancreatectomyPancreatic NeoplasmsPrognosisRetrospective StudiesSurvival RateTime FactorsTomography, X-Ray ComputedUnited StatesConceptsIntraductal papillary mucinous neoplasmInternational consensus guidelinesMalignant intraductal papillary mucinous neoplasmPapillary mucinous neoplasmConsensus guidelinesMucinous neoplasmsInvasive cancerMain duct intraductal papillary mucinous neoplasmPancreatic intraductal papillary mucinous neoplasmsPercent of patientsSingle-center reviewHigh-grade dysplasiaMayo criteriaWorse survivalPatient groupFemale sexSingle institutionMayo ClinicLower riskPatientsMultivariate analysisCancerResectionMain ductNeoplasms
2010
Endoscopic ultrasound may be unnecessary in the preoperative evaluation of intraductal papillary mucinous neoplasm
Cone M, Rea J, Diggs B, Billingsley K, Sheppard B. Endoscopic ultrasound may be unnecessary in the preoperative evaluation of intraductal papillary mucinous neoplasm. Hepato Pancreato Biliary 2010, 13: 112-116. PMID: 21241428, PMCID: PMC3044345, DOI: 10.1111/j.1477-2574.2010.00254.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiopsy, Fine-NeedleCarcinoma, Pancreatic DuctalCarcinoma, PapillaryChi-Square DistributionEndosonographyFemaleHumansLogistic ModelsMaleNeoplasms, Cystic, Mucinous, and SerousOdds RatioOregonPancreatic NeoplasmsPredictive Value of TestsPreoperative CareRetrospective StudiesTomography, X-Ray ComputedUnnecessary ProceduresConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaFine needle aspiratesPapillary mucinous neoplasmEndoscopic ultrasoundComputed tomographyCT scanMucinous neoplasmsCarcinoembryonic antigenPancreatic intraductal papillary mucinous neoplasmsDuct diameterLesion diameterPancreatic duct diameterPreoperative computed tomographyHigh-resolution CT scanningPreoperative evaluationInvasive cancerMedical recordsRadiographic criteriaStudy groupPatientsLesion sizeNeedle aspiratesMultivariate analysisCT scanningAdjuvant therapy and survival after resection of pancreatic adenocarcinoma
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma. Cancer 2010, 116: 2932-2940. PMID: 20336787, DOI: 10.1002/cncr.25082.Peer-Reviewed Original ResearchConceptsAdjuvant therapyPancreatic adenocarcinomaOverall survivalAdjuvant treatmentCox proportional hazards modelMedian overall survivalKaplan-Meier methodMedical record reviewPopulation-based cohortOngoing clinical trialsState Cancer RegistryProportional hazards modelPaucity of dataAdjuvant chemoradiationCurative intentR0 resectionMedian survivalPerformance statusComplete resectionRecord reviewCancer RegistryPathologic stageClinical trialsRegistry dataHazards modelTechniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy
Lee D, Mitchell E, Jones M, Landry G, Liem T, Sheppard B, Billingsley K, Moneta G. Techniques and results of portal vein/superior mesenteric vein reconstruction using femoral and saphenous vein during pancreaticoduodenectomy. Journal Of Vascular Surgery 2010, 51: 662-666. PMID: 20080375, DOI: 10.1016/j.jvs.2009.09.025.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaEdemaEndosonographyFemoral VeinGraft Occlusion, VascularHumansKaplan-Meier EstimateMesenteric VeinsMiddle AgedNeoplasm InvasivenessPancreatic NeoplasmsPancreaticoduodenectomyPortal VeinRegistriesReoperationSaphenous VeinTime FactorsTissue and Organ HarvestingTomography, X-Ray ComputedTreatment OutcomeUltrasonography, Doppler, DuplexVascular PatencyVascular Surgical ProceduresConceptsPV/SMV reconstructionLower extremity edemaLower extremity veinsPostoperative wound problemsLate mortalityExtremity edemaFemoral veinExtremity veinsSaphenous veinWound problemsPreoperative imagingPortal veinPV/SMV invasionSuperior mesenteric vein invasionPreoperative computed tomography (CT) imagingPV/SMVVein harvest siteLower extremity complicationsKaplan-Meier analysisGreat saphenous veinMinor operative proceduresEndoscopic ultrasound scanSuperior mesenteric vein reconstructionComputed tomography (CT) imagingPatent reconstruction
2009
Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era?
Mayo S, Austin D, Sheppard B, Mori M, Shipley D, Billingsley K. Evolving Preoperative Evaluation of Patients with Pancreatic Cancer: Does Laparoscopy Have a Role in the Current Era? Journal Of The American College Of Surgeons 2009, 208: 87-95. PMID: 19228509, DOI: 10.1016/j.jamcollsurg.2008.10.014.Peer-Reviewed Original ResearchConceptsPancreatic adenocarcinomaDiagnostic laparoscopyMetastatic diseaseSurgical explorationEndoscopic ultrasonographyDual-phase CT scanMultivariate logistic regression modelCornerstone of stagingPreoperative weight lossMedical record reviewSubset of patientsPopulation-based studyPancreatic cancer patientsState Cancer RegistrySound clinical approachCurrent imaging modalitiesCombination of CTCurrent staging techniquesLogistic regression modelsCurative intentPotential resectabilityResectable patientsLaparoscopic stagingPreoperative evaluationPrimary outcome
2008
Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era?
Enestvedt C, Mayo S, Diggs B, Mori M, Austin D, Shipley D, Sheppard B, Billingsley K. Diagnostic Laparoscopy for Patients with Potentially Resectable Pancreatic Adenocarcinoma: Is It Cost-Effective in the Current Era? Journal Of Gastrointestinal Surgery 2008, 12: 1177-1184. PMID: 18470572, DOI: 10.1007/s11605-008-0514-y.Peer-Reviewed Original ResearchConceptsDiagnostic laparoscopyPancreatic cancerPancreatic adenocarcinomaUtilization of laparoscopyResectable pancreatic cancerResectable pancreatic adenocarcinomaPancreatic cancer databaseUse of laparoscopyState Cancer RegistryMedical record dataBiliary bypassPreoperative laparoscopyResectable patientsUnderwent laparoscopyUnresectable diseaseLaparoscopic explorationPeritoneal metastasisCancer RegistryStaging modalitiesCancer DatabaseAverage hospitalLaparoscopyMedicare dataPhysician chargesPatients
2003
Outcome After Pancreaticoduodenectomy for Periampullary Cancer: An Analysis from the Veterans Affairs National Surgical Quality Improvement Program
Billingsley K, Hur K, Henderson W, Daley J, Khuri S, Bell R. Outcome After Pancreaticoduodenectomy for Periampullary Cancer: An Analysis from the Veterans Affairs National Surgical Quality Improvement Program. Journal Of Gastrointestinal Surgery 2003, 7: 484-491. PMID: 12763405, DOI: 10.1016/s1091-255x(03)00067-2.Peer-Reviewed Original ResearchConceptsNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramVeterans Affairs Healthcare SystemQuality Improvement ProgramPeriampullary cancerAdverse outcomesRisk factorsVeterans Affairs National Surgical Quality Improvement ProgramVA National Surgical Quality Improvement ProgramPre-defined complicationsPostoperative mortality ratePreoperative risk factorsPreoperative serum albuminMain outcome measuresRisk-adjusted comparisonsDifferent health care systemsVA Medical CenterLogistic regression analysisHealth care systemPancreaticoduodenectomy outcomesPostoperative mortalityAnesthesiologists classificationPostoperative deathsSeptic complicationsIntraoperative variables